Market closedNon-fractional
Pulmonx/LUNG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Ticker
LUNG
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Redwood City, United States
Employees
279
Website
pulmonx.com
Pulmonx Metrics
BasicAdvanced
$304M
Market cap
-
P/E ratio
-$1.54
EPS
0.66
Beta
-
Dividend rate
Price and volume
Market cap
$304M
Beta
0.66
Financial strength
Current ratio
6.947
Quick ratio
5.979
Long term debt to equity
29.55
Total debt to equity
36.718
Interest coverage (TTM)
-16.95%
Management effectiveness
Return on assets (TTM)
-20.52%
Return on equity (TTM)
-46.17%
Valuation
Price to revenue (TTM)
4.107
Price to book
2.73
Price to tangible book (TTM)
2.79
Price to free cash flow (TTM)
-7.898
Growth
Revenue change (TTM)
27.14%
Earnings per share change (TTM)
-2.86%
3-year revenue growth (CAGR)
29.82%
3-year earnings per share growth (CAGR)
-8.82%
What the Analysts think about Pulmonx
Analyst Ratings
Majority rating from 5 analysts.
Pulmonx Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$19M
-2.08%
Net income
-$14M
-0.72%
Profit margin
-72.87%
1.39%
Pulmonx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.43
-$0.39
-$0.36
-$0.36
-
Expected
-$0.44
-$0.43
-$0.41
-$0.46
-$0.42
Surprise
-1.56%
-8.84%
-11.58%
-21.98%
-
Pulmonx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pulmonx stock?
Pulmonx (LUNG) has a market cap of $304M as of July 27, 2024.
What is the P/E ratio for Pulmonx stock?
The price to earnings (P/E) ratio for Pulmonx (LUNG) stock is 0 as of July 27, 2024.
Does Pulmonx stock pay dividends?
No, Pulmonx (LUNG) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Pulmonx dividend payment date?
Pulmonx (LUNG) stock does not pay dividends to its shareholders.
What is the beta indicator for Pulmonx?
Pulmonx (LUNG) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Pulmonx stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.